Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Trending in China: Should Chinese School Employees be Punished for Celebrating Thanksgiving?
China Exempts Tesla Model Y from Purchase Tax
GL Ventures Leads $265m Series C Round in Chinese SaaS Edtech Firm EEO
In 165 countries, China's Beidou eclipses American GPS
China On Cusp of Becoming Third Ever Country to Collect Lunar Samples as Chang’e 5 Prepares for Moon Landing
JD.com Among Bidders for Japanese Skincare Brand Fancl’s Asian Business: Reuters
Trending in China: Did Sichuan Forget to Tell Chongqing About Their Joint Olympic Bid?
Alibaba’s Healthcare Unit Finds Tonic for Profits
Trending in China: Beijing Tackles Parking Shortage With Shared Spaces
Chinese Wireless Telecoms Operators Join Forces to Build 5G Base Stations to Reduce Costs
Ruhnn, Another U.S.-Listed Chinese Company Looks to Go Private
Unicorns surge to 500 in number as US and China account for 70%
Trending in China: Social Media Comes Out in Support of High Quality Fakes
Xiaomi-Backed IoT-Enabled Appliance Maker Sees Revenues Grow While Profits Slump
Chinese Startup WeRide Reports Promising Robotaxi Results
Trending in China: God recalls his hand – tributes to Maradona from Chinese social media after his death
Tesla to Manufacture Electric Car Chargers in China
China Restricts Livestreaming Spending and Blocks Underage Users from Tipping Performers
TikTok Granted One-Week Extension of Forced-Sale Deadline
Chinese Online Language Educator 51Talk Speaks the Language of Profit
China Approves First Biosimilar of Foreign Drug, Breaking Roche Monopoly

By Wang Luyao and Tang Ziyi / Feb 27, 2019 06:16 PM / Business & Tech

China’s National Medical Products Administration announced Monday that it has approved the country's first biosimilar drug — a copy of Roche’s drug Rituxan for treatment for lymphoma.

Biosimilars are nearly identical copies of biologics -- medicines made from living cells that must be stored under special conditions— already approved by a regulator.

The biosimilar drug made by Fosun Pharma’s joint venture subsidiary Shanghai Henlius Biotech will break the monopoly of Switzerland’s Roche, which has been the only supplier of Rituxan in China.

In 2017, Rituxan accounted for 1.73 billion yuan ($258.6 million) of Roche’s China sales, after the drug was added into the government-backed insurance reimbursement scheme, said Fosun Pharma in a statement.


Share this article
Open WeChat and scan the QR code